Copyright
©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Jun 5, 2025; 16(2): 101268
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.101268
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.101268
Table 2 Inflammatory bowel disease -related outcomes, n (%)
| Total sample (n = 61) | Active agent (n = 40) | Placebo (n = 21) | P value | |
| Biochemical flare | 8 (13.1) | 4 (10) | 4 (19.0) | 0.43 |
| Steroid use or escalation of therapy | 8 (13.1) | 4 (10) | 4 (19.0) | 0.43 |
| Biochemical flare or steroid or escalation of therapy | 10 (16.4) | 5 (12.5) | 5 (23.8) | 0.29 |
- Citation: Fennessy A, Doyle M, Boland A, Bourke R, O'Connor A. Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel diseases in absence of inflammation (train-IBD trial). World J Gastrointest Pharmacol Ther 2025; 16(2): 101268
- URL: https://www.wjgnet.com/2150-5349/full/v16/i2/101268.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i2.101268